1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)
| Autor: | Tolmeijer, S.H., Kwan, E.M., Ng, S.W.S., Joshua, A., Emmett, L., Crumbaker, M., Hamid, A.A., Anton, A., Horvath, L.G., Chan, J., Bressel, M., Buteau, J.P., Dhiantravan, N., Ayati, N., Keerthikumar, S., Goode, D., Hicks, R., Hofman, M.S., Wyatt, A.W., Sandhu, S.K. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S975-S976 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|